M
Michele Caraglia
Researcher at Seconda Università degli Studi di Napoli
Publications - 562
Citations - 24508
Michele Caraglia is an academic researcher from Seconda Università degli Studi di Napoli. The author has contributed to research in topics: Cancer & Cancer cell. The author has an hindex of 67, co-authored 525 publications receiving 20615 citations. Previous affiliations of Michele Caraglia include Temple University & Magna Græcia University.
Papers
More filters
Journal ArticleDOI
Synergistic Antitumor Activity of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Gefitinib and IFN-α in Head and Neck Cancer Cells In vitro and In vivo
Francesca Bruzzese,Elena Di Gennaro,Antonio Avallone,Stefano Pepe,Claudio Arra,Michele Caraglia,Pierosandro Tagliaferri,Alfredo Budillon +7 more
TL;DR: The observed cooperative antitumor effects could be, at least in part, explained by the inhibition exerted by gefitinib of an IFN-α-induced EGF-dependent survival pathway, which involves extracellular signal-regulated kinase activation.
Journal ArticleDOI
Single nucleotide polymorphisms of ABCC5 and ABCG1 transporter genes correlate to irinotecan-associated gastrointestinal toxicity in colorectal cancer patients: a DMET microarray profiling study.
Maria Teresa Di Martino,Mariamena Arbitrio,Emanuela Leone,Pietro Hiram Guzzi,Maria Saveria Rotundo,Domenico Ciliberto,Vera Tomaino,Fernanda Fabiani,Danilo Talarico,Pasquale Sperlongano,Patrizia Doldo,Mario Cannataro,Michele Caraglia,Pierfrancesco Tassone,Pierosandro Tagliaferri +14 more
TL;DR: 3 SNPs mapping in ABCG1, ABCC5 and OATP1B1/SLCO1 B1 transporter genes associated with GI toxicity induced by irinotecan in mCRC patients are identified expanding the available knowledge of irinogenomics.
Journal ArticleDOI
The farnesyl transferase inhibitor R115777 (Zarnestra) synergistically enhances growth inhibition and apoptosis induced on epidermoid cancer cells by Zoledronic acid (Zometa) and Pamidronate.
Michele Caraglia,Anna Maria D'Alessandro,M. Marra,G. Giuberti,Giovanni Vitale,Caterina Viscomi,Annamaria Colao,Salvatore Del Prete,Pierosandro Tagliaferri,Pierfrancesco Tassone,Alfredo Budillon,Salvatore Venuta,Alberto Abbruzzese +12 more
TL;DR: The combination of BPs and FTI leads to enhanced antitumor activity at clinically achievable drug concentrations that resides in the inhibition of farnesylation-dependent survival pathways and warrants further studies for clinical translation.
Journal ArticleDOI
Low-dose metronomic oral administration of vinorelbine in the first-line treatment of elderly patients with metastatic breast cancer.
Raffaele Addeo,Alessandro Sgambato,Gregorio Cennamo,Liliana Montella,Vincenzo Faiola,Alberto Abbruzzese,Elena Capasso,Luigi Leo,Gerardo Botti,Michele Caraglia,Salvatore Del Prete +10 more
TL;DR: The fractionated administration of oral VNB is well tolerated and presents promising activity in elderly patients with metastatic cancer, warranting further investigation in combination with other chemotherapy agents.
Journal ArticleDOI
Slow Release Lanreotide in Combination with Interferon-α2b in the Treatment of Symptomatic Advanced Medullary Thyroid Carcinoma
Giovanni Vitale,Pierosandro Tagliaferri,Michele Caraglia,Erminia Rampone,Antonio Ciccarelli,Angelo Raffaele Bianco,Alberto Abbruzzese,Giovanni Lupoli +7 more
TL;DR: The combination of lanreotide with interferon had a major impact on clinical symptoms and was well tolerated and coupled with a decrease of 50% or more in serum calcitonin levels in three of seven patients.